Cargando…

Impact of pasireotide on postoperative pancreatic fistulas following distal resections

PURPOSE: Postoperative pancreatic fistula (POPF), a difficult complication after surgery, can cause peripancreatic fluid collection and infections in the operative area. In addition, pancreatic fluid is corrosive and can lead to postoperative bleeding. Clinically significant grade B and C fistulas (...

Descripción completa

Detalles Bibliográficos
Autores principales: Vuorela, Tiina, Mustonen, H., Kokkola, A., Haglund, C., Seppanen, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106579/
https://www.ncbi.nlm.nih.gov/pubmed/33474568
http://dx.doi.org/10.1007/s00423-021-02083-2
_version_ 1783689807649570816
author Vuorela, Tiina
Mustonen, H.
Kokkola, A.
Haglund, C.
Seppanen, H.
author_facet Vuorela, Tiina
Mustonen, H.
Kokkola, A.
Haglund, C.
Seppanen, H.
author_sort Vuorela, Tiina
collection PubMed
description PURPOSE: Postoperative pancreatic fistula (POPF), a difficult complication after surgery, can cause peripancreatic fluid collection and infections in the operative area. In addition, pancreatic fluid is corrosive and can lead to postoperative bleeding. Clinically significant grade B and C fistulas (CR-POPF) increase postoperative morbidity, resulting in a prolonged hospital stay. Delaying adjuvant therapy due to fistula formation in cancer patients can affect their prognosis. In this study, we aimed to determine if pasireotide affects fistula formation, and the severity of other complications in patients following pancreatic distal resections. DATA AND METHODS: Between 2000 and 2016, 258 distal pancreatectomies were performed at Helsinki University Hospital and were included in our analysis. Pasireotide was administered to patients undergoing distal resections between July 2014 and December 2016. Patients received 900-μg pasireotide administered twice daily perioperatively. Other patients who received octreotide treatment were analyzed separately. Complications such as fistulas (POPF), delayed gastric emptying (DGE), postpancreatectomy hemorrhage (PPH), reoperations, and mortality were recorded and analyzed 90 days postoperatively. RESULTS: Overall, 47 (18%) patients received pasireotide and 31 (12%) octreotide, while 180 patients (70%) who received neither constituted the control group. There were 40 (16%) clinically relevant grade B and C POPFs: seven (15%) in the pasireotide group, three (10%) in the octreotide group, and 30 (17%) in the control group (p = 0.739). Severe complications categorized as Clavien–Dindo grade III or IV were recorded in 64 (25%) patients: 17 (27%) in the pasireotide group, 4 (6%) in the octreotide group, and 43 (67%) in the control group (p = 0.059). We found no 90-day mortality. CONCLUSIONS: In this study, pasireotide did not reduce clinically relevant POPFs or severe complications following pancreatic distal resection.
format Online
Article
Text
id pubmed-8106579
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81065792021-05-24 Impact of pasireotide on postoperative pancreatic fistulas following distal resections Vuorela, Tiina Mustonen, H. Kokkola, A. Haglund, C. Seppanen, H. Langenbecks Arch Surg Original Article PURPOSE: Postoperative pancreatic fistula (POPF), a difficult complication after surgery, can cause peripancreatic fluid collection and infections in the operative area. In addition, pancreatic fluid is corrosive and can lead to postoperative bleeding. Clinically significant grade B and C fistulas (CR-POPF) increase postoperative morbidity, resulting in a prolonged hospital stay. Delaying adjuvant therapy due to fistula formation in cancer patients can affect their prognosis. In this study, we aimed to determine if pasireotide affects fistula formation, and the severity of other complications in patients following pancreatic distal resections. DATA AND METHODS: Between 2000 and 2016, 258 distal pancreatectomies were performed at Helsinki University Hospital and were included in our analysis. Pasireotide was administered to patients undergoing distal resections between July 2014 and December 2016. Patients received 900-μg pasireotide administered twice daily perioperatively. Other patients who received octreotide treatment were analyzed separately. Complications such as fistulas (POPF), delayed gastric emptying (DGE), postpancreatectomy hemorrhage (PPH), reoperations, and mortality were recorded and analyzed 90 days postoperatively. RESULTS: Overall, 47 (18%) patients received pasireotide and 31 (12%) octreotide, while 180 patients (70%) who received neither constituted the control group. There were 40 (16%) clinically relevant grade B and C POPFs: seven (15%) in the pasireotide group, three (10%) in the octreotide group, and 30 (17%) in the control group (p = 0.739). Severe complications categorized as Clavien–Dindo grade III or IV were recorded in 64 (25%) patients: 17 (27%) in the pasireotide group, 4 (6%) in the octreotide group, and 43 (67%) in the control group (p = 0.059). We found no 90-day mortality. CONCLUSIONS: In this study, pasireotide did not reduce clinically relevant POPFs or severe complications following pancreatic distal resection. Springer Berlin Heidelberg 2021-01-20 2021 /pmc/articles/PMC8106579/ /pubmed/33474568 http://dx.doi.org/10.1007/s00423-021-02083-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Vuorela, Tiina
Mustonen, H.
Kokkola, A.
Haglund, C.
Seppanen, H.
Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title_full Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title_fullStr Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title_full_unstemmed Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title_short Impact of pasireotide on postoperative pancreatic fistulas following distal resections
title_sort impact of pasireotide on postoperative pancreatic fistulas following distal resections
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106579/
https://www.ncbi.nlm.nih.gov/pubmed/33474568
http://dx.doi.org/10.1007/s00423-021-02083-2
work_keys_str_mv AT vuorelatiina impactofpasireotideonpostoperativepancreaticfistulasfollowingdistalresections
AT mustonenh impactofpasireotideonpostoperativepancreaticfistulasfollowingdistalresections
AT kokkolaa impactofpasireotideonpostoperativepancreaticfistulasfollowingdistalresections
AT haglundc impactofpasireotideonpostoperativepancreaticfistulasfollowingdistalresections
AT seppanenh impactofpasireotideonpostoperativepancreaticfistulasfollowingdistalresections